QIAGEN N.V.(QGEN)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #1,143 of 2,961 stocksTOP 50%
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
QGEN Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for QIAGEN N.V. (QGEN), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores QGEN at 56.6/100 on a 32-signal composite quality model, placing it at rank #1,143 of 2,961 stocks — the top half of the AI-ranked universe. Based on the latest XBRL financial filings (FY 2025), QIAGEN N.V. reports quarterly revenue of $2.1B, net income of $424.9M, an operating margin of 22.3%. Top institutional holders of QGEN by reported 13-F value include WELLINGTON MANAGEMENT GROUP LLP, PRICE T ROWE ASSOCIATES, PRINCIPAL FINANCIAL GROUP, based on the most recent SEC filings. QGEN trades on the NYSE exchange and files with the SEC under CIK 1015820. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate QGEN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for QIAGEN N.V. directly from SEC EDGAR. QIAGEN N.V.'s 13F Pro composite quality score has ranged between 48 and 57 since 2026, currently 56.6 — an improving long-term trajectory across 47 quarterly and live scoring snapshots.
Revenue
FY 2025
$2.1B
Net Income
FY 2025
$424.9M
Free Cash Flow
FY 2025
$453.3M
Operating Margin
FY 2025
22.3%
ROIC
FY 2025
8.6%
D/E Ratio
FY 2025
0.44
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+5.7% YoYNet Income
+408.3% YoYOperating Income
+376.8% YoYEPS (Diluted)
+424.3% YoYTotal Assets
+10.4% YoYTotal Debt
-14.9% YoYOp. Cash Flow
-2.9% YoYFree Cash Flow
-10.5% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $2.09B +5.7% | $1.98B +0.7% | $1.97B -8.2% | $2.14B -4.9% | $2.25B +20.4% | $1.87B |
| Net Income | $424.9M +408.3% | $83.6M -75.5% | $341.3M -19.4% | $423.2M -17.4% | $512.6M +42.7% | $359.2M |
| Operating Income | $465.9M +376.8% | $97.7M -76.2% | $409.9M -22.9% | $531.5M -15.7% | $630.1M +63.1% | $386.4M |
| EPS (Diluted) | $1.94 +424.3% | $0.37 -75.0% | $1.48 -19.6% | $1.84 -16.7% | $2.21 +44.4% | $1.53 |
| Total Assets | $6.28B +10.4% | $5.69B -7.0% | $6.12B -2.7% | $6.29B +2.3% | $6.15B +4.7% | $5.87B |
| Total Debt | $1.65B -14.9% | $1.94B -7.4% | $2.10B -6.8% | $2.25B -19.3% | $2.79B +41.9% | $1.97B |
| Operating Cash Flow | $654.3M -2.9% | $673.6M +46.6% | $459.5M -35.8% | $715.3M +11.9% | $639.0M +39.6% | $457.8M |
| Free Cash Flow | $453.3M -10.5% | $506.4M +63.5% | $309.7M -47.1% | $586.0M +30.5% | $449.1M +38.2% | $325.0M |
Get alerted when QGEN's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for QIAGEN N.V. including:
Top Institutional Holders of QGEN
WELLINGTON MANAGEMENT GROUP LLP
$484.2M12,406,763 shPRICE T ROWE ASSOCIATES INC /MD/
$444.0M11,354,379 shPRINCIPAL FINANCIAL GROUP INC
$260.0M6,648,681 shVANGUARD CAPITAL MANAGEMENT LLC
$240.2M6,209,904 shBlackRock, Inc.
$230.9M5,905,678 shMORGAN STANLEY
$197.2M5,042,391 shEARNEST PARTNERS LLC
$178.8M4,573,455 shGOLDMAN SACHS GROUP INC
$173.7M4,443,674 shNORGES BANK
$168.0M4,325,135 shMILLENNIUM MANAGEMENT LLC
$150.4M3,845,605 sh
| Fund | Value | Shares |
|---|---|---|
| WELLINGTON MANAGEMENT GROUP LLP | $484.2M | 12,406,763 |
| PRICE T ROWE ASSOCIATES INC /MD/ | $444.0M | 11,354,379 |
| PRINCIPAL FINANCIAL GROUP INC | $260.0M | 6,648,681 |
| VANGUARD CAPITAL MANAGEMENT LLC | $240.2M | 6,209,904 |
| BlackRock, Inc. | $230.9M | 5,905,678 |
| MORGAN STANLEY | $197.2M | 5,042,391 |
| EARNEST PARTNERS LLC | $178.8M | 4,573,455 |
| GOLDMAN SACHS GROUP INC | $173.7M | 4,443,674 |
| NORGES BANK | $168.0M | 4,325,135 |
| MILLENNIUM MANAGEMENT LLC | $150.4M | 3,845,605 |
Companies Similar to QGEN
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
BIOGEN INC.
Royalty Pharma plc
ALIGN TECHNOLOGY INC
MSA Safety Inc
Ingevity Corp
ASTRAZENECA PLC
IRADIMED CORP
REGENERON PHARMACEUTICALS, INC.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put QGEN on your watchlist
Track score changes the day QIAGEN N.V. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is QGEN a good stock to buy?
13F Pro's AI-powered analysis of QIAGEN N.V. (QGEN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for QGEN are available on the QGEN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. QGEN is classified as a mid company.
Which hedge funds own QGEN?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling QGEN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of QIAGEN N.V.'s investment landscape.